Trial Outcomes & Findings for Early GLP-1 Receptor Agonist and SGLT2 Inhibitor Add-On Strategies in Adults With Obesity, Type 2 Diabetes, Cardiovascular-Kidney-Metabolic Syndrome Stage 2-3, and Metabolic Dysfunction-Associated Steatotic Liver Disease (NCT NCT07566299)
NCT ID: NCT07566299
Last Updated: 2026-06-25
Results Overview
All-cause mortality from the 90-day landmark date through up to 60 months of follow-up in the propensity score-matched cohort for Comparison 1, comparing adults with obesity, type 2 diabetes, CKM syndrome stage 2-3, and MASLD who initiated GLP-1 RA therapy with early SGLT2i add-on versus those who initiated GLP-1 RA therapy without early SGLT2i add-on (monotherapy).
Recruitment status
COMPLETED
Target enrollment
118805 participants
Primary outcome timeframe
From 90 days after treatment initiation through up to 60 months of follow-up
Results posted on
2026-06-25
Participant Flow
Participants were retrospectively identified from the TriNetX US Collaborative Network using de-identified electronic health records. Eligible adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who newly initiated GLP-1 RA or SGLT2i therapy between January 1, 2017 and March 31, 2026 were included based on prespecified eligibility criteria.
Enrollment and Participant Flow counts reflect unique participants in the overall study population, classified into four mutually exclusive treatment-strategy cohorts according to background therapy and 90-day add-on status. Participants were counted once in the Participant Flow module. Comparator-specific propensity score-matched cohorts were defined separately for prespecified pairwise outcome analyses and are reported in the Baseline Characteristics and Outcome Measures sections.
Participant milestones
| Measure |
GLP-1 RA With SGLT2i Add-On
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and added an SGLT2 inhibitor within 90 days after treatment initiation. This cohort served as the early GLP-1 RA + SGLT2i combination exposure cohort in the overall study population and represents the unique participants with early SGLT2i add-on after GLP-1 RA initiation.
|
GLP-1 RA Monotherapy
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and did not receive early add-on therapy with an SGLT2 inhibitor within 90 days after treatment initiation. Participants could receive routine clinical care, including DPP-4 inhibitors, sulfonylureas, or insulin. This cohort represents the unique participants with GLP-1 RA background therapy without early SGLT2i add-on.
|
SGLT2i With GLP-1 RA Add-On
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated SGLT2 inhibitor therapy and added a GLP-1 receptor agonist within 90 days after treatment initiation. This cohort served as the early SGLT2i + GLP-1 RA combination exposure cohort in the overall study population and represents the unique participants with early GLP-1 RA add-on after SGLT2i initiation.
|
SGLT2i Monotherapy
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated SGLT2 inhibitor therapy and did not receive early add-on therapy with a GLP-1 receptor agonist within 90 days after treatment initiation. Participants could receive routine clinical care, including DPP-4 inhibitors, sulfonylureas, or insulin. This cohort represents the unique participants with SGLT2i background therapy without early GLP-1 RA add-on.
|
|---|---|---|---|---|
|
Overall Study
STARTED
|
14542
|
57166
|
13680
|
33417
|
|
Overall Study
COMPLETED
|
14542
|
57166
|
13680
|
33417
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
Baseline characteristics by cohort
| Measure |
GLP-1 RA With SGLT2i Add-On (Comparison 1)
n=14487 Participants
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and added an SGLT2 inhibitor within 90 days after treatment initiation. This group represents the propensity score-matched GLP-1 RA + SGLT2i add-on cohort for Comparison 1 (vs GLP-1 RA monotherapy).
|
GLP-1 RA Monotherapy (Comparison 1)
n=14487 Participants
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and did not receive early add-on therapy with an SGLT2 inhibitor within 90 days after treatment initiation. Participants could receive routine clinical care, including DPP-4 inhibitors, sulfonylureas, or insulin. This group represents the propensity score-matched GLP-1 RA monotherapy comparator cohort for Comparison 1.
|
GLP-1 RA With SGLT2i Add-On (Comparison 2)
n=13012 Participants
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and added an SGLT2 inhibitor within 90 days after treatment initiation. This group represents the propensity score-matched GLP-1 RA + SGLT2i add-on cohort for Comparison 2 (vs GLP-1 RA with usual care).
|
GLP-1 RA With Usual Care (Comparison 2)
n=13012 Participants
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and added a DPP-4 inhibitor, sulfonylurea, or insulin within 90 days after treatment initiation, without initiation of an SGLT2 inhibitor during the same window. This group represents the propensity score-matched GLP-1 RA with usual care comparator cohort for Comparison 2.
|
SGLT2i With GLP-1 RA Add-On (Comparison 3)
n=13490 Participants
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated SGLT2 inhibitor therapy and added a GLP-1 receptor agonist within 90 days after treatment initiation. This group represents the propensity score-matched SGLT2i + GLP-1 RA add-on cohort for Comparison 3 (vs SGLT2i monotherapy).
|
SGLT2i Monotherapy (Comparison 3)
n=13490 Participants
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated SGLT2 inhibitor therapy and did not receive early add-on therapy with a GLP-1 receptor agonist within 90 days after treatment initiation. Participants could receive routine clinical care, including DPP-4 inhibitors, sulfonylureas, or insulin. This group represents the propensity score-matched SGLT2i monotherapy comparator cohort for Comparison 3.
|
SGLT2i With GLP-1 RA Add-On (Comparison 4)
n=11155 Participants
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated SGLT2 inhibitor therapy and added a GLP-1 receptor agonist within 90 days after treatment initiation. This group represents the propensity score-matched SGLT2i + GLP-1 RA add-on cohort for Comparison 4 (vs SGLT2i with usual care).
|
SGLT2i With Usual Care (Comparison 4)
n=11155 Participants
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated SGLT2 inhibitor therapy and added a DPP-4 inhibitor, sulfonylurea, or insulin within 90 days after treatment initiation, without initiation of a GLP-1 receptor agonist during the same window. This group represents the propensity score-matched SGLT2i with usual care comparator cohort for Comparison 4.
|
Total
n=104288 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|
|
Age, Customized
18-44 years (Comparison 1)
|
2222 Participants
n=14487 Participants • Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
2238 Participants
n=14487 Participants • Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
4460 Participants
n=28974 Participants • Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
|
Age, Customized
45-64 years (Comparison 1)
|
8299 Participants
n=14487 Participants • Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
8239 Participants
n=14487 Participants • Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
16538 Participants
n=28974 Participants • Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
|
Age, Customized
≥65 years (Comparison 1)
|
3955 Participants
n=14487 Participants • Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
4003 Participants
n=14487 Participants • Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
7958 Participants
n=28974 Participants • Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
|
Age, Customized
18-44 years (Comparison 2)
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
1980 Participants
n=13012 Participants • Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
1983 Participants
n=13012 Participants • Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
3963 Participants
n=26024 Participants • Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
|
Age, Customized
45-64 years (Comparison 2)
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
7315 Participants
n=13012 Participants • Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
7277 Participants
n=13012 Participants • Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
14592 Participants
n=26024 Participants • Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
|
Age, Customized
≥65 years (Comparison 2)
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
3706 Participants
n=13012 Participants • Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
3740 Participants
n=13012 Participants • Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
7446 Participants
n=26024 Participants • Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
|
Age, Customized
18-44 years (Comparison 3)
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
1719 Participants
n=13490 Participants • Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
1721 Participants
n=13490 Participants • Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
3440 Participants
n=26980 Participants • Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
|
Age, Customized
45-64 years (Comparison 3)
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
7733 Participants
n=13490 Participants • Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
7704 Participants
n=13490 Participants • Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
15437 Participants
n=26980 Participants • Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
|
Age, Customized
≥65 years (Comparison 3)
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
4038 Participants
n=13490 Participants • Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
4065 Participants
n=13490 Participants • Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
8103 Participants
n=26980 Participants • Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
|
Age, Customized
18-44 years (Comparison 4)
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
1195 Participants
n=11155 Participants • Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
1190 Participants
n=11155 Participants • Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
2385 Participants
n=22310 Participants • Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
|
Age, Customized
45-64 years (Comparison 4)
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
6082 Participants
n=11155 Participants • Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
6071 Participants
n=11155 Participants • Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
12153 Participants
n=22310 Participants • Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
|
Age, Customized
≥65 years (Comparison 4)
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
3874 Participants
n=11155 Participants • Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
3891 Participants
n=11155 Participants • Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
7765 Participants
n=22310 Participants • Age categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
|
Sex/Gender, Customized
Male (Comparison 1)
|
6722 Participants
n=14487 Participants • Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
6710 Participants
n=14487 Participants • Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
13432 Participants
n=28974 Participants • Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
|
HbA1c ≥7%
HbA1c ≥7% (Comparison 1)
|
10739 Participants
n=14487 Participants • Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
10946 Participants
n=14487 Participants • Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
21685 Participants
n=28974 Participants • Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
|
Sex/Gender, Customized
Female (Comparison 1)
|
7760 Participants
n=14487 Participants • Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
7775 Participants
n=14487 Participants • Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
15535 Participants
n=28974 Participants • Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
|
Ethnicity (NIH/OMB)
Comparison 1 · Hispanic or Latino
|
1583 Participants
n=14487 Participants • Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
1513 Participants
n=14487 Participants • Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
3096 Participants
n=28974 Participants • Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
|
Sex/Gender, Customized
Unknown or Not Reported (Comparison 1)
|
5 Participants
n=14487 Participants • Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
2 Participants
n=14487 Participants • Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
7 Participants
n=28974 Participants • Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
|
Sex/Gender, Customized
Male (Comparison 2)
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
5647 Participants
n=13012 Participants • Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
5694 Participants
n=13012 Participants • Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
11341 Participants
n=26024 Participants • Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
|
Sex/Gender, Customized
Female (Comparison 2)
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
7362 Participants
n=13012 Participants • Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
7314 Participants
n=13012 Participants • Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
14676 Participants
n=26024 Participants • Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
|
Sex/Gender, Customized
Unknown or Not Reported (Comparison 2)
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
3 Participants
n=13012 Participants • Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
4 Participants
n=13012 Participants • Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
7 Participants
n=26024 Participants • Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
|
Sex/Gender, Customized
Male (Comparison 3)
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
6813 Participants
n=13490 Participants • Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
6875 Participants
n=13490 Participants • Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
13688 Participants
n=26980 Participants • Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
|
Ethnicity (NIH/OMB)
Comparison 1 · Not Hispanic or Latino
|
10268 Participants
n=14487 Participants • Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
10319 Participants
n=14487 Participants • Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
20587 Participants
n=28974 Participants • Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
|
Sex/Gender, Customized
Female (Comparison 3)
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
6677 Participants
n=13490 Participants • Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
6617 Participants
n=13490 Participants • Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
13294 Participants
n=26980 Participants • Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
|
Sex/Gender, Customized
Unknown or Not Reported (Comparison 3)
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
n=13490 Participants • Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
n=13490 Participants • Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
n=26980 Participants • Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
|
Sex/Gender, Customized
Male (Comparison 4)
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
5679 Participants
n=11155 Participants • Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
5711 Participants
n=11155 Participants • Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
11390 Participants
n=22310 Participants • Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
|
Sex/Gender, Customized
Female (Comparison 4)
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
5472 Participants
n=11155 Participants • Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
5441 Participants
n=11155 Participants • Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
10913 Participants
n=22310 Participants • Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
|
Sex/Gender, Customized
Unknown or Not Reported (Comparison 4)
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
0 Participants
Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
4 Participants
n=11155 Participants • Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
3 Participants
n=11155 Participants • Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
7 Participants
n=22310 Participants • Sex/gender categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed. A small number of participants in the source system export were not resolved into the displayed sex/gender strata and are therefore reported under "Unknown or Not Reported" so that category counts sum to the analyzed population.
|
|
Ethnicity (NIH/OMB)
Comparison 1 · Unknown or Not Reported
|
2636 Participants
n=14487 Participants • Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
2655 Participants
n=14487 Participants • Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
5291 Participants
n=28974 Participants • Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
|
Ethnicity (NIH/OMB)
Comparison 2 · Hispanic or Latino
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
1388 Participants
n=13012 Participants • Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
1416 Participants
n=13012 Participants • Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
2804 Participants
n=26024 Participants • Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
|
Ethnicity (NIH/OMB)
Comparison 2 · Not Hispanic or Latino
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
9252 Participants
n=13012 Participants • Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
9254 Participants
n=13012 Participants • Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
18506 Participants
n=26024 Participants • Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
|
Ethnicity (NIH/OMB)
Comparison 2 · Unknown or Not Reported
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
2372 Participants
n=13012 Participants • Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
2342 Participants
n=13012 Participants • Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
4714 Participants
n=26024 Participants • Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
|
Ethnicity (NIH/OMB)
Comparison 3 · Hispanic or Latino
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
1538 Participants
n=13490 Participants • Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
1518 Participants
n=13490 Participants • Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
3056 Participants
n=26980 Participants • Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
|
Ethnicity (NIH/OMB)
Comparison 3 · Not Hispanic or Latino
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
9511 Participants
n=13490 Participants • Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
9545 Participants
n=13490 Participants • Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
19056 Participants
n=26980 Participants • Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
|
Ethnicity (NIH/OMB)
Comparison 3 · Unknown or Not Reported
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
2441 Participants
n=13490 Participants • Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
2427 Participants
n=13490 Participants • Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
4868 Participants
n=26980 Participants • Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
|
Ethnicity (NIH/OMB)
Comparison 4 · Hispanic or Latino
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
1160 Participants
n=11155 Participants • Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
1156 Participants
n=11155 Participants • Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
2316 Participants
n=22310 Participants • Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
|
Ethnicity (NIH/OMB)
Comparison 4 · Not Hispanic or Latino
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
8036 Participants
n=11155 Participants • Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
8019 Participants
n=11155 Participants • Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
16055 Participants
n=22310 Participants • Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
|
Ethnicity (NIH/OMB)
Comparison 4 · Unknown or Not Reported
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
1959 Participants
n=11155 Participants • Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
1980 Participants
n=11155 Participants • Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
3939 Participants
n=22310 Participants • Ethnicity categories are reported separately for each prespecified pairwise comparison. For each comparison-specific row, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
|
HbA1c ≥7%
HbA1c ≥7% (Comparison 2)
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
9655 Participants
n=13012 Participants • Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
9733 Participants
n=13012 Participants • Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
19388 Participants
n=26024 Participants • Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
|
HbA1c ≥7%
HbA1c ≥7% (Comparison 3)
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
9800 Participants
n=13490 Participants • Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
9896 Participants
n=13490 Participants • Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
19696 Participants
n=26980 Participants • Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
|
HbA1c ≥7%
HbA1c ≥7% (Comparison 4)
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
7983 Participants
n=11155 Participants • Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
8026 Participants
n=11155 Participants • Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
16009 Participants
n=22310 Participants • Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
|
eGFR <60 mL/min/1.73 m²
eGFR <60 mL/min/1.73 m² (Comparison 1)
|
4570 Participants
n=14487 Participants • Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
4480 Participants
n=14487 Participants • Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
9050 Participants
n=28974 Participants • Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
|
eGFR <60 mL/min/1.73 m²
eGFR <60 mL/min/1.73 m² (Comparison 2)
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
4143 Participants
n=13012 Participants • Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
4198 Participants
n=13012 Participants • Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
8341 Participants
n=26024 Participants • Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
|
eGFR <60 mL/min/1.73 m²
eGFR <60 mL/min/1.73 m² (Comparison 3)
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
4392 Participants
n=13490 Participants • Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
4321 Participants
n=13490 Participants • Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
8713 Participants
n=26980 Participants • Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
|
eGFR <60 mL/min/1.73 m²
eGFR <60 mL/min/1.73 m² (Comparison 4)
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
3998 Participants
n=11155 Participants • Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
3973 Participants
n=11155 Participants • Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
7971 Participants
n=22310 Participants • Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
|
BMI ≥30 kg/m²
BMI ≥30 kg/m² (Comparison 1)
|
10902 Participants
n=14487 Participants • Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
10853 Participants
n=14487 Participants • Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
21755 Participants
n=28974 Participants • Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
|
BMI ≥30 kg/m²
BMI ≥30 kg/m² (Comparison 2)
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
9967 Participants
n=13012 Participants • Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
9933 Participants
n=13012 Participants • Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
19900 Participants
n=26024 Participants • Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
|
BMI ≥30 kg/m²
BMI ≥30 kg/m² (Comparison 3)
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
9891 Participants
n=13490 Participants • Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
9838 Participants
n=13490 Participants • Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
19729 Participants
n=26980 Participants • Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
|
BMI ≥30 kg/m²
BMI ≥30 kg/m² (Comparison 4)
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
0 Participants
Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
8078 Participants
n=11155 Participants • Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
8076 Participants
n=11155 Participants • Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
16154 Participants
n=22310 Participants • Data are reported separately for each prespecified pairwise comparison. For each comparison-specific measure, data are shown only for the two relevant arms; all other arms are assigned 0 participants analyzed.
|
PRIMARY outcome
Timeframe: From 90 days after treatment initiation through up to 60 months of follow-upPopulation: Participants analyzed were members of the corresponding comparison-specific propensity score-matched cohort who were at risk at the start of the 60-month assessment window. Participants with the outcome before the assessment window were excluded. Therefore, the number analyzed may differ across outcomes.
All-cause mortality from the 90-day landmark date through up to 60 months of follow-up in the propensity score-matched cohort for Comparison 1, comparing adults with obesity, type 2 diabetes, CKM syndrome stage 2-3, and MASLD who initiated GLP-1 RA therapy with early SGLT2i add-on versus those who initiated GLP-1 RA therapy without early SGLT2i add-on (monotherapy).
Outcome measures
| Measure |
GLP-1 RA With SGLT2i Add-On (Comparison 2)
n=14358 Participants
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and added an SGLT2 inhibitor within 90 days after treatment initiation. This group represents the propensity score-matched GLP-1 RA + SGLT2i add-on cohort for Comparison 2 (vs GLP-1 RA with usual care).
|
GLP-1 RA Monotherapy (Comparison 1)
n=14389 Participants
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and did not receive early add-on therapy with an SGLT2 inhibitor within 90 days after treatment initiation. Participants could receive routine clinical care, including DPP-4 inhibitors, sulfonylureas, or insulin. This group represents the propensity score-matched GLP-1 RA monotherapy comparator cohort for Comparison 1.
|
|---|---|---|
|
All-cause Mortality (Comparison 1)
|
278 participants with event
|
396 participants with event
|
PRIMARY outcome
Timeframe: From 90 days after treatment initiation through up to 60 months of follow-upPopulation: Participants analyzed were members of the corresponding comparison-specific propensity score-matched cohort who were at risk at the start of the 60-month assessment window. Participants with the outcome before the assessment window were excluded. Therefore, the number analyzed may differ across outcomes.
All-cause mortality from the 90-day landmark date through up to 60 months of follow-up in the propensity score-matched cohort for Comparison 2, comparing adults with obesity, type 2 diabetes, CKM syndrome stage 2-3, and MASLD who initiated GLP-1 RA therapy with early SGLT2i add-on versus those who initiated GLP-1 RA therapy with usual care (DPP-4 inhibitor, sulfonylurea, or insulin add-on).
Outcome measures
| Measure |
GLP-1 RA With SGLT2i Add-On (Comparison 2)
n=12897 Participants
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and added an SGLT2 inhibitor within 90 days after treatment initiation. This group represents the propensity score-matched GLP-1 RA + SGLT2i add-on cohort for Comparison 2 (vs GLP-1 RA with usual care).
|
GLP-1 RA Monotherapy (Comparison 1)
n=12865 Participants
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and did not receive early add-on therapy with an SGLT2 inhibitor within 90 days after treatment initiation. Participants could receive routine clinical care, including DPP-4 inhibitors, sulfonylureas, or insulin. This group represents the propensity score-matched GLP-1 RA monotherapy comparator cohort for Comparison 1.
|
|---|---|---|
|
All-cause Mortality (Comparison 2)
|
248 participants with event
|
425 participants with event
|
PRIMARY outcome
Timeframe: From 90 days after treatment initiation through up to 60 months of follow-upPopulation: Participants analyzed were members of the corresponding comparison-specific propensity score-matched cohort who were at risk at the start of the 60-month assessment window. Participants with the outcome before the assessment window were excluded. Therefore, the number analyzed may differ across outcomes.
All-cause mortality from the 90-day landmark date through up to 60 months of follow-up in the propensity score-matched cohort for Comparison 3, comparing adults with obesity, type 2 diabetes, CKM syndrome stage 2-3, and MASLD who initiated SGLT2i therapy with early GLP-1 RA add-on versus those who initiated SGLT2i therapy without early GLP-1 RA add-on (monotherapy).
Outcome measures
| Measure |
GLP-1 RA With SGLT2i Add-On (Comparison 2)
n=13359 Participants
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and added an SGLT2 inhibitor within 90 days after treatment initiation. This group represents the propensity score-matched GLP-1 RA + SGLT2i add-on cohort for Comparison 2 (vs GLP-1 RA with usual care).
|
GLP-1 RA Monotherapy (Comparison 1)
n=13345 Participants
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and did not receive early add-on therapy with an SGLT2 inhibitor within 90 days after treatment initiation. Participants could receive routine clinical care, including DPP-4 inhibitors, sulfonylureas, or insulin. This group represents the propensity score-matched GLP-1 RA monotherapy comparator cohort for Comparison 1.
|
|---|---|---|
|
All-cause Mortality (Comparison 3)
|
290 participants with event
|
418 participants with event
|
PRIMARY outcome
Timeframe: From 90 days after treatment initiation through up to 60 months of follow-upPopulation: Participants analyzed were members of the corresponding comparison-specific propensity score-matched cohort who were at risk at the start of the 60-month assessment window. Participants with the outcome before the assessment window were excluded. Therefore, the number analyzed may differ across outcomes.
All-cause mortality from the 90-day landmark date through up to 60 months of follow-up in the propensity score-matched cohort for Comparison 4, comparing adults with obesity, type 2 diabetes, CKM syndrome stage 2-3, and MASLD who initiated SGLT2i therapy with early GLP-1 RA add-on versus those who initiated SGLT2i therapy with usual care (DPP-4 inhibitor, sulfonylurea, or insulin add-on).
Outcome measures
| Measure |
GLP-1 RA With SGLT2i Add-On (Comparison 2)
n=11034 Participants
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and added an SGLT2 inhibitor within 90 days after treatment initiation. This group represents the propensity score-matched GLP-1 RA + SGLT2i add-on cohort for Comparison 2 (vs GLP-1 RA with usual care).
|
GLP-1 RA Monotherapy (Comparison 1)
n=10974 Participants
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and did not receive early add-on therapy with an SGLT2 inhibitor within 90 days after treatment initiation. Participants could receive routine clinical care, including DPP-4 inhibitors, sulfonylureas, or insulin. This group represents the propensity score-matched GLP-1 RA monotherapy comparator cohort for Comparison 1.
|
|---|---|---|
|
All-cause Mortality (Comparison 4)
|
270 participants with event
|
402 participants with event
|
SECONDARY outcome
Timeframe: From 90 days after treatment initiation through up to 60 months of follow-upPopulation: Participants analyzed were members of the corresponding comparison-specific propensity score-matched cohort who were at risk at the start of the 60-month assessment window. Participants with the outcome before the assessment window were excluded. Therefore, the number analyzed may differ across outcomes.
Composite of acute myocardial infarction, cardiac arrest, intracerebral or intracranial hemorrhage, and cerebral infarction from the 90-day landmark date through up to 60 months of follow-up in the propensity score-matched cohort for Comparison 1, comparing GLP-1 RA with early SGLT2i add-on versus GLP-1 RA monotherapy.
Outcome measures
| Measure |
GLP-1 RA With SGLT2i Add-On (Comparison 2)
n=12952 Participants
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and added an SGLT2 inhibitor within 90 days after treatment initiation. This group represents the propensity score-matched GLP-1 RA + SGLT2i add-on cohort for Comparison 2 (vs GLP-1 RA with usual care).
|
GLP-1 RA Monotherapy (Comparison 1)
n=13053 Participants
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and did not receive early add-on therapy with an SGLT2 inhibitor within 90 days after treatment initiation. Participants could receive routine clinical care, including DPP-4 inhibitors, sulfonylureas, or insulin. This group represents the propensity score-matched GLP-1 RA monotherapy comparator cohort for Comparison 1.
|
|---|---|---|
|
Major Adverse Cardiovascular Events (Comparison 1)
|
464 participants with event
|
524 participants with event
|
SECONDARY outcome
Timeframe: From 90 days after treatment initiation through up to 60 months of follow-upPopulation: Participants analyzed were members of the corresponding comparison-specific propensity score-matched cohort who were at risk at the start of the 60-month assessment window. Participants with the outcome before the assessment window were excluded. Therefore, the number analyzed may differ across outcomes.
Composite of acute myocardial infarction, cardiac arrest, intracerebral or intracranial hemorrhage, and cerebral infarction from the 90-day landmark date through up to 60 months of follow-up in the propensity score-matched cohort for Comparison 2, comparing GLP-1 RA with early SGLT2i add-on versus GLP-1 RA with usual care.
Outcome measures
| Measure |
GLP-1 RA With SGLT2i Add-On (Comparison 2)
n=11634 Participants
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and added an SGLT2 inhibitor within 90 days after treatment initiation. This group represents the propensity score-matched GLP-1 RA + SGLT2i add-on cohort for Comparison 2 (vs GLP-1 RA with usual care).
|
GLP-1 RA Monotherapy (Comparison 1)
n=11577 Participants
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and did not receive early add-on therapy with an SGLT2 inhibitor within 90 days after treatment initiation. Participants could receive routine clinical care, including DPP-4 inhibitors, sulfonylureas, or insulin. This group represents the propensity score-matched GLP-1 RA monotherapy comparator cohort for Comparison 1.
|
|---|---|---|
|
Major Adverse Cardiovascular Events (Comparison 2)
|
425 participants with event
|
515 participants with event
|
SECONDARY outcome
Timeframe: From 90 days after treatment initiation through up to 60 months of follow-upPopulation: Participants analyzed were members of the corresponding comparison-specific propensity score-matched cohort who were at risk at the start of the 60-month assessment window. Participants with the outcome before the assessment window were excluded. Therefore, the number analyzed may differ across outcomes.
Composite of acute myocardial infarction, cardiac arrest, intracerebral or intracranial hemorrhage, and cerebral infarction from the 90-day landmark date through up to 60 months of follow-up in the propensity score-matched cohort for Comparison 3, comparing SGLT2i with early GLP-1 RA add-on versus SGLT2i monotherapy.
Outcome measures
| Measure |
GLP-1 RA With SGLT2i Add-On (Comparison 2)
n=11903 Participants
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and added an SGLT2 inhibitor within 90 days after treatment initiation. This group represents the propensity score-matched GLP-1 RA + SGLT2i add-on cohort for Comparison 2 (vs GLP-1 RA with usual care).
|
GLP-1 RA Monotherapy (Comparison 1)
n=11971 Participants
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and did not receive early add-on therapy with an SGLT2 inhibitor within 90 days after treatment initiation. Participants could receive routine clinical care, including DPP-4 inhibitors, sulfonylureas, or insulin. This group represents the propensity score-matched GLP-1 RA monotherapy comparator cohort for Comparison 1.
|
|---|---|---|
|
Major Adverse Cardiovascular Events (Comparison 3)
|
438 participants with event
|
497 participants with event
|
SECONDARY outcome
Timeframe: From 90 days after treatment initiation through up to 60 months of follow-upPopulation: Participants analyzed were members of the corresponding comparison-specific propensity score-matched cohort who were at risk at the start of the 60-month assessment window. Participants with the outcome before the assessment window were excluded. Therefore, the number analyzed may differ across outcomes.
Composite of acute myocardial infarction, cardiac arrest, intracerebral or intracranial hemorrhage, and cerebral infarction from the 90-day landmark date through up to 60 months of follow-up in the propensity score-matched cohort for Comparison 4, comparing SGLT2i with early GLP-1 RA add-on versus SGLT2i with usual care.
Outcome measures
| Measure |
GLP-1 RA With SGLT2i Add-On (Comparison 2)
n=9677 Participants
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and added an SGLT2 inhibitor within 90 days after treatment initiation. This group represents the propensity score-matched GLP-1 RA + SGLT2i add-on cohort for Comparison 2 (vs GLP-1 RA with usual care).
|
GLP-1 RA Monotherapy (Comparison 1)
n=9632 Participants
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and did not receive early add-on therapy with an SGLT2 inhibitor within 90 days after treatment initiation. Participants could receive routine clinical care, including DPP-4 inhibitors, sulfonylureas, or insulin. This group represents the propensity score-matched GLP-1 RA monotherapy comparator cohort for Comparison 1.
|
|---|---|---|
|
Major Adverse Cardiovascular Events (Comparison 4)
|
394 participants with event
|
445 participants with event
|
SECONDARY outcome
Timeframe: From 90 days after treatment initiation through up to 60 months of follow-upPopulation: Participants analyzed were members of the corresponding comparison-specific propensity score-matched cohort who were at risk at the start of the 60-month assessment window. Participants with the outcome before the assessment window were excluded. Therefore, the number analyzed may differ across outcomes.
Composite of end-stage kidney disease, dialysis dependence or initiation, kidney failure, and dialysis-related procedures from the 90-day landmark date through up to 60 months of follow-up in the propensity score-matched cohort for Comparison 1, comparing GLP-1 RA with early SGLT2i add-on versus GLP-1 RA monotherapy.
Outcome measures
| Measure |
GLP-1 RA With SGLT2i Add-On (Comparison 2)
n=14303 Participants
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and added an SGLT2 inhibitor within 90 days after treatment initiation. This group represents the propensity score-matched GLP-1 RA + SGLT2i add-on cohort for Comparison 2 (vs GLP-1 RA with usual care).
|
GLP-1 RA Monotherapy (Comparison 1)
n=14276 Participants
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and did not receive early add-on therapy with an SGLT2 inhibitor within 90 days after treatment initiation. Participants could receive routine clinical care, including DPP-4 inhibitors, sulfonylureas, or insulin. This group represents the propensity score-matched GLP-1 RA monotherapy comparator cohort for Comparison 1.
|
|---|---|---|
|
Major Adverse Kidney Events (Comparison 1)
|
112 participants with event
|
151 participants with event
|
SECONDARY outcome
Timeframe: From 90 days after treatment initiation through up to 60 months of follow-upPopulation: Participants analyzed were members of the corresponding comparison-specific propensity score-matched cohort who were at risk at the start of the 60-month assessment window. Participants with the outcome before the assessment window were excluded. Therefore, the number analyzed may differ across outcomes.
Composite of end-stage kidney disease, dialysis dependence or initiation, kidney failure, and dialysis-related procedures from the 90-day landmark date through up to 60 months of follow-up in the propensity score-matched cohort for Comparison 2, comparing GLP-1 RA with early SGLT2i add-on versus GLP-1 RA with usual care.
Outcome measures
| Measure |
GLP-1 RA With SGLT2i Add-On (Comparison 2)
n=12848 Participants
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and added an SGLT2 inhibitor within 90 days after treatment initiation. This group represents the propensity score-matched GLP-1 RA + SGLT2i add-on cohort for Comparison 2 (vs GLP-1 RA with usual care).
|
GLP-1 RA Monotherapy (Comparison 1)
n=12798 Participants
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and did not receive early add-on therapy with an SGLT2 inhibitor within 90 days after treatment initiation. Participants could receive routine clinical care, including DPP-4 inhibitors, sulfonylureas, or insulin. This group represents the propensity score-matched GLP-1 RA monotherapy comparator cohort for Comparison 1.
|
|---|---|---|
|
Major Adverse Kidney Events (Comparison 2)
|
103 participants with event
|
158 participants with event
|
SECONDARY outcome
Timeframe: From 90 days after treatment initiation through up to 60 months of follow-upPopulation: Participants analyzed were members of the corresponding comparison-specific propensity score-matched cohort who were at risk at the start of the 60-month assessment window. Participants with the outcome before the assessment window were excluded. Therefore, the number analyzed may differ across outcomes.
Composite of end-stage kidney disease, dialysis dependence or initiation, kidney failure, and dialysis-related procedures from the 90-day landmark date through up to 60 months of follow-up in the propensity score-matched cohort for Comparison 3, comparing SGLT2i with early GLP-1 RA add-on versus SGLT2i monotherapy.
Outcome measures
| Measure |
GLP-1 RA With SGLT2i Add-On (Comparison 2)
n=13297 Participants
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and added an SGLT2 inhibitor within 90 days after treatment initiation. This group represents the propensity score-matched GLP-1 RA + SGLT2i add-on cohort for Comparison 2 (vs GLP-1 RA with usual care).
|
GLP-1 RA Monotherapy (Comparison 1)
n=13302 Participants
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and did not receive early add-on therapy with an SGLT2 inhibitor within 90 days after treatment initiation. Participants could receive routine clinical care, including DPP-4 inhibitors, sulfonylureas, or insulin. This group represents the propensity score-matched GLP-1 RA monotherapy comparator cohort for Comparison 1.
|
|---|---|---|
|
Major Adverse Kidney Events (Comparison 3)
|
92 participants with event
|
129 participants with event
|
SECONDARY outcome
Timeframe: From 90 days after treatment initiation through up to 60 months of follow-upPopulation: Participants analyzed were members of the corresponding comparison-specific propensity score-matched cohort who were at risk at the start of the 60-month assessment window. Participants with the outcome before the assessment window were excluded. Therefore, the number analyzed may differ across outcomes.
Composite of end-stage kidney disease, dialysis dependence or initiation, kidney failure, and dialysis-related procedures from the 90-day landmark date through up to 60 months of follow-up in the propensity score-matched cohort for Comparison 4, comparing SGLT2i with early GLP-1 RA add-on versus SGLT2i with usual care.
Outcome measures
| Measure |
GLP-1 RA With SGLT2i Add-On (Comparison 2)
n=10977 Participants
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and added an SGLT2 inhibitor within 90 days after treatment initiation. This group represents the propensity score-matched GLP-1 RA + SGLT2i add-on cohort for Comparison 2 (vs GLP-1 RA with usual care).
|
GLP-1 RA Monotherapy (Comparison 1)
n=10949 Participants
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and did not receive early add-on therapy with an SGLT2 inhibitor within 90 days after treatment initiation. Participants could receive routine clinical care, including DPP-4 inhibitors, sulfonylureas, or insulin. This group represents the propensity score-matched GLP-1 RA monotherapy comparator cohort for Comparison 1.
|
|---|---|---|
|
Major Adverse Kidney Events (Comparison 4)
|
83 participants with event
|
97 participants with event
|
SECONDARY outcome
Timeframe: From 90 days after treatment initiation through up to 60 months of follow-upPopulation: Participants analyzed were members of the corresponding comparison-specific propensity score-matched cohort who were at risk at the start of the 60-month assessment window. Participants with the outcome before the assessment window were excluded. Therefore, the number analyzed may differ across outcomes.
Composite of hepatic decompensation (ascites, hepatic encephalopathy, variceal bleeding, spontaneous bacterial peritonitis, hepatic failure, hepatorenal syndrome), hepatocellular carcinoma, and liver transplantation from the 90-day landmark date through up to 60 months of follow-up in the propensity score-matched cohort for Comparison 1, comparing GLP-1 RA with early SGLT2i add-on versus GLP-1 RA monotherapy.
Outcome measures
| Measure |
GLP-1 RA With SGLT2i Add-On (Comparison 2)
n=14037 Participants
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and added an SGLT2 inhibitor within 90 days after treatment initiation. This group represents the propensity score-matched GLP-1 RA + SGLT2i add-on cohort for Comparison 2 (vs GLP-1 RA with usual care).
|
GLP-1 RA Monotherapy (Comparison 1)
n=14060 Participants
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and did not receive early add-on therapy with an SGLT2 inhibitor within 90 days after treatment initiation. Participants could receive routine clinical care, including DPP-4 inhibitors, sulfonylureas, or insulin. This group represents the propensity score-matched GLP-1 RA monotherapy comparator cohort for Comparison 1.
|
|---|---|---|
|
Major Adverse Liver Outcomes (Comparison 1)
|
196 participants with event
|
226 participants with event
|
SECONDARY outcome
Timeframe: From 90 days after treatment initiation through up to 60 months of follow-upPopulation: Participants analyzed were members of the corresponding comparison-specific propensity score-matched cohort who were at risk at the start of the 60-month assessment window. Participants with the outcome before the assessment window were excluded. Therefore, the number analyzed may differ across outcomes.
Composite of hepatic decompensation, hepatocellular carcinoma, and liver transplantation from the 90-day landmark date through up to 60 months of follow-up in the propensity score-matched cohort for Comparison 2, comparing GLP-1 RA with early SGLT2i add-on versus GLP-1 RA with usual care.
Outcome measures
| Measure |
GLP-1 RA With SGLT2i Add-On (Comparison 2)
n=12599 Participants
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and added an SGLT2 inhibitor within 90 days after treatment initiation. This group represents the propensity score-matched GLP-1 RA + SGLT2i add-on cohort for Comparison 2 (vs GLP-1 RA with usual care).
|
GLP-1 RA Monotherapy (Comparison 1)
n=12564 Participants
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and did not receive early add-on therapy with an SGLT2 inhibitor within 90 days after treatment initiation. Participants could receive routine clinical care, including DPP-4 inhibitors, sulfonylureas, or insulin. This group represents the propensity score-matched GLP-1 RA monotherapy comparator cohort for Comparison 1.
|
|---|---|---|
|
Major Adverse Liver Outcomes (Comparison 2)
|
180 participants with event
|
245 participants with event
|
SECONDARY outcome
Timeframe: From 90 days after treatment initiation through up to 60 months of follow-upPopulation: Participants analyzed were members of the corresponding comparison-specific propensity score-matched cohort who were at risk at the start of the 60-month assessment window. Participants with the outcome before the assessment window were excluded. Therefore, the number analyzed may differ across outcomes.
Composite of hepatic decompensation, hepatocellular carcinoma, and liver transplantation from the 90-day landmark date through up to 60 months of follow-up in the propensity score-matched cohort for Comparison 3, comparing SGLT2i with early GLP-1 RA add-on versus SGLT2i monotherapy.
Outcome measures
| Measure |
GLP-1 RA With SGLT2i Add-On (Comparison 2)
n=13008 Participants
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and added an SGLT2 inhibitor within 90 days after treatment initiation. This group represents the propensity score-matched GLP-1 RA + SGLT2i add-on cohort for Comparison 2 (vs GLP-1 RA with usual care).
|
GLP-1 RA Monotherapy (Comparison 1)
n=13041 Participants
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and did not receive early add-on therapy with an SGLT2 inhibitor within 90 days after treatment initiation. Participants could receive routine clinical care, including DPP-4 inhibitors, sulfonylureas, or insulin. This group represents the propensity score-matched GLP-1 RA monotherapy comparator cohort for Comparison 1.
|
|---|---|---|
|
Major Adverse Liver Outcomes (Comparison 3)
|
166 participants with event
|
216 participants with event
|
SECONDARY outcome
Timeframe: From 90 days after treatment initiation through up to 60 months of follow-upPopulation: Participants analyzed were members of the corresponding comparison-specific propensity score-matched cohort who were at risk at the start of the 60-month assessment window. Participants with the outcome before the assessment window were excluded. Therefore, the number analyzed may differ across outcomes.
Composite of hepatic decompensation, hepatocellular carcinoma, and liver transplantation from the 90-day landmark date through up to 60 months of follow-up in the propensity score-matched cohort for Comparison 4, comparing SGLT2i with early GLP-1 RA add-on versus SGLT2i with usual care.
Outcome measures
| Measure |
GLP-1 RA With SGLT2i Add-On (Comparison 2)
n=10701 Participants
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and added an SGLT2 inhibitor within 90 days after treatment initiation. This group represents the propensity score-matched GLP-1 RA + SGLT2i add-on cohort for Comparison 2 (vs GLP-1 RA with usual care).
|
GLP-1 RA Monotherapy (Comparison 1)
n=10679 Participants
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and did not receive early add-on therapy with an SGLT2 inhibitor within 90 days after treatment initiation. Participants could receive routine clinical care, including DPP-4 inhibitors, sulfonylureas, or insulin. This group represents the propensity score-matched GLP-1 RA monotherapy comparator cohort for Comparison 1.
|
|---|---|---|
|
Major Adverse Liver Outcomes (Comparison 4)
|
141 participants with event
|
201 participants with event
|
Adverse Events
GLP-1 RA With SGLT2i Add-On (Comparison 1)
Serious events: 608 serious events
Other events: 0 other events
Deaths: 278 deaths
GLP-1 RA Monotherapy (Comparison 1)
Serious events: 715 serious events
Other events: 0 other events
Deaths: 396 deaths
GLP-1 RA With SGLT2i Add-On (Comparison 2)
Serious events: 574 serious events
Other events: 0 other events
Deaths: 248 deaths
GLP-1 RA With Usual Care (Comparison 2)
Serious events: 754 serious events
Other events: 0 other events
Deaths: 425 deaths
SGLT2i With GLP-1 RA Add-On (Comparison 3)
Serious events: 548 serious events
Other events: 0 other events
Deaths: 290 deaths
SGLT2i Monotherapy (Comparison 3)
Serious events: 667 serious events
Other events: 0 other events
Deaths: 418 deaths
SGLT2i With GLP-1 RA Add-On (Comparison 4)
Serious events: 484 serious events
Other events: 0 other events
Deaths: 270 deaths
SGLT2i With Usual Care (Comparison 4)
Serious events: 613 serious events
Other events: 0 other events
Deaths: 402 deaths
Serious adverse events
| Measure |
GLP-1 RA With SGLT2i Add-On (Comparison 1)
n=14303 participants at risk
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and added an SGLT2 inhibitor within 90 days after treatment initiation. This group represents the propensity score-matched GLP-1 RA + SGLT2i add-on cohort for Comparison 1 (vs GLP-1 RA monotherapy).
|
GLP-1 RA Monotherapy (Comparison 1)
n=14276 participants at risk
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and did not receive early add-on therapy with an SGLT2 inhibitor within 90 days after treatment initiation. Participants could receive routine clinical care, including DPP-4 inhibitors, sulfonylureas, or insulin. This group represents the propensity score-matched GLP-1 RA monotherapy comparator cohort for Comparison 1.
|
GLP-1 RA With SGLT2i Add-On (Comparison 2)
n=12848 participants at risk
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and added an SGLT2 inhibitor within 90 days after treatment initiation. This group represents the propensity score-matched GLP-1 RA + SGLT2i add-on cohort for Comparison 2 (vs GLP-1 RA with usual care).
|
GLP-1 RA With Usual Care (Comparison 2)
n=12798 participants at risk
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and added a DPP-4 inhibitor, sulfonylurea, or insulin within 90 days after treatment initiation, without initiation of an SGLT2 inhibitor during the same window. This group represents the propensity score-matched GLP-1 RA with usual care comparator cohort for Comparison 2.
|
SGLT2i With GLP-1 RA Add-On (Comparison 3)
n=13297 participants at risk
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated SGLT2 inhibitor therapy and added a GLP-1 receptor agonist within 90 days after treatment initiation. This group represents the propensity score-matched SGLT2i + GLP-1 RA add-on cohort for Comparison 3 (vs SGLT2i monotherapy).
|
SGLT2i Monotherapy (Comparison 3)
n=13302 participants at risk
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated SGLT2 inhibitor therapy and did not receive early add-on therapy with a GLP-1 receptor agonist within 90 days after treatment initiation. Participants could receive routine clinical care, including DPP-4 inhibitors, sulfonylureas, or insulin. This group represents the propensity score-matched SGLT2i monotherapy comparator cohort for Comparison 3.
|
SGLT2i With GLP-1 RA Add-On (Comparison 4)
n=10977 participants at risk
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated SGLT2 inhibitor therapy and added a GLP-1 receptor agonist within 90 days after treatment initiation. This group represents the propensity score-matched SGLT2i + GLP-1 RA add-on cohort for Comparison 4 (vs SGLT2i with usual care).
|
SGLT2i With Usual Care (Comparison 4)
n=10949 participants at risk
Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated SGLT2 inhibitor therapy and added a DPP-4 inhibitor, sulfonylurea, or insulin within 90 days after treatment initiation, without initiation of a GLP-1 receptor agonist during the same window. This group represents the propensity score-matched SGLT2i with usual care comparator cohort for Comparison 4.
|
|---|---|---|---|---|---|---|---|---|
|
Cardiac disorders
Major Adverse Cardiovascular Events
|
3.6%
464/12952 • From the 90-day landmark date through up to 60 months of follow-up
Adverse event information was derived from routinely collected EHR data during 60 months of follow-up in this retrospective analysis. Systematic clinical trial AE surveillance was not conducted. AE assessment was limited to all-cause mortality and prespecified EHR-defined serious clinical events, including MACE, MAKE, and MALO. Other non-serious AEs were not assessed.
|
4.0%
524/13053 • From the 90-day landmark date through up to 60 months of follow-up
Adverse event information was derived from routinely collected EHR data during 60 months of follow-up in this retrospective analysis. Systematic clinical trial AE surveillance was not conducted. AE assessment was limited to all-cause mortality and prespecified EHR-defined serious clinical events, including MACE, MAKE, and MALO. Other non-serious AEs were not assessed.
|
3.7%
425/11634 • From the 90-day landmark date through up to 60 months of follow-up
Adverse event information was derived from routinely collected EHR data during 60 months of follow-up in this retrospective analysis. Systematic clinical trial AE surveillance was not conducted. AE assessment was limited to all-cause mortality and prespecified EHR-defined serious clinical events, including MACE, MAKE, and MALO. Other non-serious AEs were not assessed.
|
4.4%
515/11577 • From the 90-day landmark date through up to 60 months of follow-up
Adverse event information was derived from routinely collected EHR data during 60 months of follow-up in this retrospective analysis. Systematic clinical trial AE surveillance was not conducted. AE assessment was limited to all-cause mortality and prespecified EHR-defined serious clinical events, including MACE, MAKE, and MALO. Other non-serious AEs were not assessed.
|
3.7%
438/11903 • From the 90-day landmark date through up to 60 months of follow-up
Adverse event information was derived from routinely collected EHR data during 60 months of follow-up in this retrospective analysis. Systematic clinical trial AE surveillance was not conducted. AE assessment was limited to all-cause mortality and prespecified EHR-defined serious clinical events, including MACE, MAKE, and MALO. Other non-serious AEs were not assessed.
|
4.2%
497/11971 • From the 90-day landmark date through up to 60 months of follow-up
Adverse event information was derived from routinely collected EHR data during 60 months of follow-up in this retrospective analysis. Systematic clinical trial AE surveillance was not conducted. AE assessment was limited to all-cause mortality and prespecified EHR-defined serious clinical events, including MACE, MAKE, and MALO. Other non-serious AEs were not assessed.
|
4.1%
394/9677 • From the 90-day landmark date through up to 60 months of follow-up
Adverse event information was derived from routinely collected EHR data during 60 months of follow-up in this retrospective analysis. Systematic clinical trial AE surveillance was not conducted. AE assessment was limited to all-cause mortality and prespecified EHR-defined serious clinical events, including MACE, MAKE, and MALO. Other non-serious AEs were not assessed.
|
4.6%
445/9632 • From the 90-day landmark date through up to 60 months of follow-up
Adverse event information was derived from routinely collected EHR data during 60 months of follow-up in this retrospective analysis. Systematic clinical trial AE surveillance was not conducted. AE assessment was limited to all-cause mortality and prespecified EHR-defined serious clinical events, including MACE, MAKE, and MALO. Other non-serious AEs were not assessed.
|
|
Renal and urinary disorders
Major Adverse Kidney Events
|
0.78%
112/14303 • From the 90-day landmark date through up to 60 months of follow-up
Adverse event information was derived from routinely collected EHR data during 60 months of follow-up in this retrospective analysis. Systematic clinical trial AE surveillance was not conducted. AE assessment was limited to all-cause mortality and prespecified EHR-defined serious clinical events, including MACE, MAKE, and MALO. Other non-serious AEs were not assessed.
|
1.1%
151/14276 • From the 90-day landmark date through up to 60 months of follow-up
Adverse event information was derived from routinely collected EHR data during 60 months of follow-up in this retrospective analysis. Systematic clinical trial AE surveillance was not conducted. AE assessment was limited to all-cause mortality and prespecified EHR-defined serious clinical events, including MACE, MAKE, and MALO. Other non-serious AEs were not assessed.
|
0.80%
103/12848 • From the 90-day landmark date through up to 60 months of follow-up
Adverse event information was derived from routinely collected EHR data during 60 months of follow-up in this retrospective analysis. Systematic clinical trial AE surveillance was not conducted. AE assessment was limited to all-cause mortality and prespecified EHR-defined serious clinical events, including MACE, MAKE, and MALO. Other non-serious AEs were not assessed.
|
1.2%
158/12798 • From the 90-day landmark date through up to 60 months of follow-up
Adverse event information was derived from routinely collected EHR data during 60 months of follow-up in this retrospective analysis. Systematic clinical trial AE surveillance was not conducted. AE assessment was limited to all-cause mortality and prespecified EHR-defined serious clinical events, including MACE, MAKE, and MALO. Other non-serious AEs were not assessed.
|
0.69%
92/13297 • From the 90-day landmark date through up to 60 months of follow-up
Adverse event information was derived from routinely collected EHR data during 60 months of follow-up in this retrospective analysis. Systematic clinical trial AE surveillance was not conducted. AE assessment was limited to all-cause mortality and prespecified EHR-defined serious clinical events, including MACE, MAKE, and MALO. Other non-serious AEs were not assessed.
|
0.97%
129/13302 • From the 90-day landmark date through up to 60 months of follow-up
Adverse event information was derived from routinely collected EHR data during 60 months of follow-up in this retrospective analysis. Systematic clinical trial AE surveillance was not conducted. AE assessment was limited to all-cause mortality and prespecified EHR-defined serious clinical events, including MACE, MAKE, and MALO. Other non-serious AEs were not assessed.
|
0.76%
83/10977 • From the 90-day landmark date through up to 60 months of follow-up
Adverse event information was derived from routinely collected EHR data during 60 months of follow-up in this retrospective analysis. Systematic clinical trial AE surveillance was not conducted. AE assessment was limited to all-cause mortality and prespecified EHR-defined serious clinical events, including MACE, MAKE, and MALO. Other non-serious AEs were not assessed.
|
0.89%
97/10949 • From the 90-day landmark date through up to 60 months of follow-up
Adverse event information was derived from routinely collected EHR data during 60 months of follow-up in this retrospective analysis. Systematic clinical trial AE surveillance was not conducted. AE assessment was limited to all-cause mortality and prespecified EHR-defined serious clinical events, including MACE, MAKE, and MALO. Other non-serious AEs were not assessed.
|
|
Hepatobiliary disorders
Major Adverse Liver Outcomes
|
1.4%
196/14037 • From the 90-day landmark date through up to 60 months of follow-up
Adverse event information was derived from routinely collected EHR data during 60 months of follow-up in this retrospective analysis. Systematic clinical trial AE surveillance was not conducted. AE assessment was limited to all-cause mortality and prespecified EHR-defined serious clinical events, including MACE, MAKE, and MALO. Other non-serious AEs were not assessed.
|
1.6%
226/14060 • From the 90-day landmark date through up to 60 months of follow-up
Adverse event information was derived from routinely collected EHR data during 60 months of follow-up in this retrospective analysis. Systematic clinical trial AE surveillance was not conducted. AE assessment was limited to all-cause mortality and prespecified EHR-defined serious clinical events, including MACE, MAKE, and MALO. Other non-serious AEs were not assessed.
|
1.4%
180/12599 • From the 90-day landmark date through up to 60 months of follow-up
Adverse event information was derived from routinely collected EHR data during 60 months of follow-up in this retrospective analysis. Systematic clinical trial AE surveillance was not conducted. AE assessment was limited to all-cause mortality and prespecified EHR-defined serious clinical events, including MACE, MAKE, and MALO. Other non-serious AEs were not assessed.
|
2.0%
245/12564 • From the 90-day landmark date through up to 60 months of follow-up
Adverse event information was derived from routinely collected EHR data during 60 months of follow-up in this retrospective analysis. Systematic clinical trial AE surveillance was not conducted. AE assessment was limited to all-cause mortality and prespecified EHR-defined serious clinical events, including MACE, MAKE, and MALO. Other non-serious AEs were not assessed.
|
1.3%
166/13008 • From the 90-day landmark date through up to 60 months of follow-up
Adverse event information was derived from routinely collected EHR data during 60 months of follow-up in this retrospective analysis. Systematic clinical trial AE surveillance was not conducted. AE assessment was limited to all-cause mortality and prespecified EHR-defined serious clinical events, including MACE, MAKE, and MALO. Other non-serious AEs were not assessed.
|
1.7%
216/13041 • From the 90-day landmark date through up to 60 months of follow-up
Adverse event information was derived from routinely collected EHR data during 60 months of follow-up in this retrospective analysis. Systematic clinical trial AE surveillance was not conducted. AE assessment was limited to all-cause mortality and prespecified EHR-defined serious clinical events, including MACE, MAKE, and MALO. Other non-serious AEs were not assessed.
|
1.3%
141/10701 • From the 90-day landmark date through up to 60 months of follow-up
Adverse event information was derived from routinely collected EHR data during 60 months of follow-up in this retrospective analysis. Systematic clinical trial AE surveillance was not conducted. AE assessment was limited to all-cause mortality and prespecified EHR-defined serious clinical events, including MACE, MAKE, and MALO. Other non-serious AEs were not assessed.
|
1.9%
201/10679 • From the 90-day landmark date through up to 60 months of follow-up
Adverse event information was derived from routinely collected EHR data during 60 months of follow-up in this retrospective analysis. Systematic clinical trial AE surveillance was not conducted. AE assessment was limited to all-cause mortality and prespecified EHR-defined serious clinical events, including MACE, MAKE, and MALO. Other non-serious AEs were not assessed.
|
Other adverse events
Adverse event data not reported
Additional Information
Yu-Nan Huang, Ph.D.
Chung Shan Medical University Hospital
Phone: 886-4-24739595
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place